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Background: Repeated administration of antibody-based therapies such as radioimmunotherapy depends on
preserved antigen expression in tumor lesions. The purpose of this study was to evaluate whether the antigen
expression in metastases observed after radioimmunotherapy differs from that of untreated primary tumors.
Findings: 30 of the 35 Brown Norway rats with syngeneic colon carcinoma treated with 400 MBq/kg
177Lu-DOTA-BR96 exhibited consistent complete response of the primary tumor. 13 animals developed metastases
that were detected after treatment. The antigen expression was reduced in 17 of 23 metastases detected after
radioimmunotherapy compared with untreated tumors. No tumors completely lacked positively stained
tumor cells.
Conclusions: Although it was not possible to demonstrate that the antigen reduction is triggered by the
radioimmunotherapy this result stress the importance of considering the risk of reduced antigen expression in
metastases after radioimmunotherapy prior to further targeted therapies.
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Treatment of primary tumors is often successful com-
pared to that of metastatic disease, which is responsible
for 90% of cancer mortality [1]. Radioimmunotherapy, the
use of radiolabeled antibodies to localize radiation to the
tumor, is considered a suitable treatment modality for
smaller metastases [2]. Repeated administrations of radio-
immunoconjugate may be required and/or beneficial in
order to reduce toxicity and improve the outcome [3].
The aim of the present study was to compare the anti-
gen expression and distribution in metastases, detected
after consistent complete response (CR) of the primary
tumor following radioimmunotherapy with 177Lu-DOTA-
BR96, to that of untreated primary tumors in a syngeneic
immunocompetent rat colon carcinoma model.* Correspondence: Erika.elgstrom@med.lu.se
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Radioimmunoconjugate and tumor model
BR96 is a monoclonal antibody which binds to the Lewis
Y antigen (Ley). Conjugation with the DOTA-chelate
(S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclodo-
decane tetraacetic acid; Macrocyclics, Dallas, TX) and
subsequent radiolabeling with 177LuCl3 solution (MDS
Nordion, Vancouver, Canada) was performed according
to Eriksson et al. [4]. The radiochemical purity of
177Lu-DOTA-BR96 was analyzed using ITLC and found
to be >97.5%. Less than 1.3% labeled aggregated frac-
tions was detected with HPLC.
Brown Norway (BN) rats were used (Harlan, Horst,
Netherlands). Animals of this rat strain are immu-
nocompetent and express the BR96 binding antigen
(Lewis Y) in some normal tissues, mainly in the epithe-
lium of the gastrointestinal tract [5], and therefore
mimic the clinical situation.
The animals were inoculated under anesthesia (Isoflur-
ane, Abbott Scandinavia AB, Solna, Sweden) with 3 x
105 BN7005-H1D2 cells (a cell line established from a
1,2-dimethylhydrazine-induced colon carcinoma in a BNal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Timing of the detection of metastatic disease.
Accumulated percentage of rats with metastatic disease observed
during the study period (n=11 of 30). At the end of the study, two
additional animals had metastases at autopsy; these are not
included in this figure. Day 0=day of injection of 177Lu-DOTA-BR96.
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The resulting local tumors were designated primary
tumors. Tumor volumes were calculated as tumor length
x tumor width2 x 0.4. All experiments were conducted
in compliance with Swedish legislation on animal rights
and protection, and were approved by the Regional
Animal Ethics Committee. The animals were housed
under standard conditions and fed with standard pellets
and fresh water, ad libitum.
Radioimmunotherapy with 177Lu-DOTA-BR96
Thirty-five male rats were treated with 400 MBq/kg
177Lu-DOTA-BR96 (150 μg DOTA-BR96 in 0.4 ml saline
with 1% human serum albumin) by intravenous injection
13-14 days after cell inoculation Group A). 11 tumor-
bearing rats were not treated (Group B). The treated
animals were monitored for up to 120 days after injec-
tion of 177Lu-DOTA-BR96. The control animals (Group
B) were euthanized and dissected on the day of adminis-
tration of radioimmunotherapy to Group A (day 0). The
median primary tumor volume on the day of treatment
was 490 mm3 (range 115-1490 mm3) and the mean body
weight was 253 g (SD 23 g).
Twice a week, body weight of the animals in Group A
was recorded, and the diameters of the primary tumors
were measured with a digital caliper under anesthesia
Consistent CR was defined as a non-palpable tumor dur-
ing the rest of the observation period. Rats were sacri-
ficed if the dimensions of the tumor exceeded 25 x 25 mm,
or at the end of the study (120 days). If body weight
decreased by more than 20% compared to normal
weight progression, or if the general health of the animal
was affected during the study, metastatic disease was
suspected and the rat was sacrificed and dissected to
confirm metastatic growth. At the time of sacrifice, all
rats were dissected systematically by the same person,
and the location and number of metastatic sites was
registered. Tumor findings were fixed in 4% paraformal-
dehyde and embedded in paraffin.
Of the 35 male BN rats treated with 400 MBq/kg
177Lu-DOTA-BR96 (Group A) 30 exhibited consistent
CR of the primary tumor. Eleven of these 30 rats devel-
oped metastatic disease and metastases were detected in
another 2 rats at autopsy at the end of the study. The
time at which metastatic disease was observed, and the
location of metastases in various organs are presented
in Figures 1 and 2. In the untreated group (Group B),
all 11 animals were dissected on day 0. None of these
animals had visible metastases at autopsy.
Antigen expression and distribution in tumors
Paraffin embedded tumors and metastases were sec-
tioned and stained with hematoxylin and eosin, and by
immunohistochemical staining for the detection of theBR96 target antigen and Ki67, a marker for proliferating
cells. In short, 4 μm thick sections were rehydrated and
antigen retrieval was performed using the PT Link pre-
treatment module (Dako) with acidic target retrieval
solution (pH 6), preheated to 65°C and then heated to
99°C for 20 min, followed by rinsing of the slides. The
sections were incubated with BR96 or Rabbit anti Ki67
(Clone SP6, NeoMarkers, Fremont, CA) diluted in Anti-
body diluent (Dako) overnight (BR96) or for 2 h (Ki67)
at room temperature. After washing, sections were incu-
bated with anti-human IgG H+L Donkey F(ab)2 HRP
(Jackson ImmunoResearch Laboratories Inc., West
Grove, PA) (for BR96 detection) or Donkey anti-rabbit
HRP (Jackson Laboratories) (for Ki67 detection) in Anti-
body diluent for 3 h (for BR96) or 1 h (for Ki67) at room
temperature. Finally, diaminobenzidine (Dako) was
added before dehydration and mounting.
Hematoxylin and eosin staining were used to evaluate
the overall tumor structure and to distinguish the tumor
cells from stromal cells in the tumor. Tumor expression
of the BR96 target antigen was scored. A score of 0 cor-
responds to less than 10% positive (strong complete
membranous staining) tumor cells, 1 to 10-50% positive
tumor cells, 2 to 50-90% positive tumor cells and 3
to more than 90% positive tumor cells. Proliferation
was evaluated in relation to the expression of the BR96
target antigen.
Immunohistochemical staining of the BR96 target
antigen was scored from 0 to 3 representing the degree
of expression (see Table 1). The results presented for
Group A are based on the 13 animals showing con-
sistent CR after treatment of the primary tumor with
177Lu-DOTA-BR96 which later developed distant metas-
tases. All the untreated primary tumors in Group B
Figure 2 Tissue localization of detected metastases. The number of animals with metastases at different locations after treatment with
177Lu-DOTA-BR96. Abdominal denotes metastases growing inside the abdominal cavity but not within a specific organ, mostly in the mesentery,
in fat tissue or in the peritoneum. Retroperitoneal metastases were found adjacent to the kidneys. The numbers within parentheses are the
number of metastases found at the specified location in the same animal.
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Group A, in which only 6 out of 23 had a score of 3
(Table 1). The other metastases in Group A had scores
of 2 (n=6), 1 (n=9) or 0 (n=2). The metastases with
reduced antigen expression showed less BR96 binding,
either in specific areas or over the whole tissue section.
None of the metastases completely lacked expression of
the BR96 target antigen.
Reduced proliferation was detected in 13 of 23 metas-
tases from rats treated with radioimmunotherapy, but
did not show any relation to the expression of the BR96
target antigen. All primary tumors (Group B) showed
high proliferation index.
In half of the cases with more than one stained metas-
tasis sample from the same animal, the BR96 target
antigen expression score was the same. An example
of different antigen expression within the same animal
is illustrated in Figure 3, showing two different metasta-
ses adjacent to the right and the left kidneys. Although
these two tumors had different BR96 target antigen
expression (scores 2 and 1) there was no difference
in proliferation.
Discussion
Primary tumors from untreated animals demonstrated
an intense homogeneous BR96 target antigen staining
pattern, and all were given a score of 3. In comparison,Table 1 Scores reflecting the BR96 target antigen expression




Metastases (from 13 rats)
B No treatment Primary tumors (from 11 rats)
a % of viable tumor cells showing strong complete membranous staining.a score of 3 was only given to 6 of the 23 distant metas-
tases in animals belonging to Group A, showing consist-
ent CR of the primary tumor after treatment with 177Lu-
DOTA-BR96 (Table 1). The metastases with reduced
antigen expression showed less BR96 binding, either in
specific areas or over the whole tissue section. None of
the metastases completely lacked expression of the BR96
target antigen. It would have been interesting to evaluate
metastases in animals not administered radioimmuno-
conjugate, but this would have required the removal of
the primary tumors to prolong the survival of these ani-
mals to allow development of metastatic disease. In un-
treated rats, the tumors reach maximal tolerable volume
on day 21-28, i.e. prior to earliest detected metastatic
disease (Figure 1). Previous attempts to surgically re-
move tumors inside the abdomen have not been success-
ful. Apart from technical difficulties, surgical removal of
the primary tumor might stimulate the growth of distant
metastases [6]. Of the same reason we have not been
able to determine whether the antigen expression of the
primary tumor becomes more heterogeneous with time
and local progression (exceeding 25 x 25 mm) for ethical
reasons.
The antigen expression was reduced in 17 of 23 of the
analyzed metastases, but it was not possible to deter-
mine whether this was due to the metastatic process
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Figure 3 Different staining pattern in metastases from the
same animal. Stained sections from two different metastases from
the same rat treated with 177Lu-DOTA-BR96. The metastases were
located retroperitoneally adjacent to the right (a and b) and left
kidneys (c and d). Staining with BR96 was scored as 2 (a) and as
1 (c), and was not related to proliferation. The results for Ki67 are
shown in b and d. Scale bars represent 50 μm.
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cells disseminate before, or as a result of, the treatment.
However, no visible metastases could be detected at time
of treatment.
Since none of the metastases completely lacked the
BR96 target antigen, it might be beneficial to repeat
radioimmunotherapy with BR96 utilizing a radionuclide
with a relatively long range, resulting in irradiation from
targeted to adjacent untargeted cells by the cross-fire
effect. However, such radionuclides are generally
regarded as unsuitable for the treatment of single cells
or cell clusters. On the other hand, studies on external
beam radiotherapy have indicated that it is not necessary
to irradiate all the cells in a tumor to obtain efficacy as a
result of the bystander effect [7,8].
In experimental studies of treatment with BR96-
doxrubicin antibody conjugates in a rat brain tumor
model, Muldoon et al. [9] reported changes in the anti-
gen staining pattern in residual tumors. The immuno-
conjugate treatment resulted in outgrowth of tumors
with areas of low or no antigen staining, as well as areas
with moderate to intense staining, while the untreated
tumors showed uniform intense staining for BR96.
Our findings indicate that during the planning of
repeated radioimmunotherapy, and/or radioimmunother-
apy in combination with other antibody therapies, it is im-
portant to consider the risk of reduced antigen expression
in metastases, as this may result in reduced targeting of
the therapeutics.
Conclusions
This study showed that the antigen expression was
reduced in 17 of the 23 metastases detected afterradioimmunotherapy compared with untreated tumors.
Although it was not possible to demonstrate that
the antigen reduction is triggered by the radioimmu-
notherapy this result stress the importance of cons-
idering the risk of reduced antigen expression in
metastases after radioimmunotherapy prior to further
targeted therapies.
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